Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
With
National Cancer Institute (NCI)
OBJECTIVES:
Primary
* Identify detectable changes in the transcriptomic or proteomic expression prior to clinical manifestations of graft-versus-host disease (GVHD) in blood samples from at-risk patients who have undergone allogeneic bone marrow transplantation.
Secondary
* Characterize changes in the transcriptome or proteome expression pattern which are predictive of clinically significant GVHD in these patients.
* Develop reliable tests which enable early intervention for these patients.
OUTLINE: Blood samples are collected prior to and just after typical onset of clinical graft-vs-host disease (GVHD) on days 1, 7-10, 20-23, 30-33, and 60 after allogeneic bone marrow transplantation. RNA is quantified and assessed by microarray analysis to identify changes to transcriptome or proteome expression and markers predictive of the onset of clinical GVHD. Samples are also stored for future analysis.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Any patient undergoing an allogeneic bone marrow transplantation at one of the participating Mayo Clinic sites